Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by farmerjaneon Apr 22, 2021 12:24am
209 Views
Post# 33042776

RE:pfizer vaccine and covid immunity waning

RE:pfizer vaccine and covid immunity waningElliott, you have to focus on your last line, "And I hope the new revs can fund Ph1 of their other genious product PMN310"
  
What you have said in the past including one week ago April 13th, the last PP Qoute" A group of renowned business magnates provided $7M in financing to Promis and stated that their due diligence indicates the technology has tremendous potential. This investment will be used to transition PMN310 into Phase 1 clinical trials for treatment of Alzhemiers disease ect...."


Messaging narrative continously changes, and no corporate objectives in partnerships with Pharma other than the same University in British Columbia obtained over how many yearS? Six? People watching if PM310 is so good why wasn't it partnered a few years ago? Are you going to use the Amyloid theory again? 


<< Previous
Bullboard Posts
Next >>